Articles tagged with Cancer Patients
Researchers developed a risk calculator using persistent homology scores from CT scans, which is the strongest predictor of overall survival among standard clinical measures. The calculator has the potential to guide clinicians in choosing treatment options and transform the way outcomes are predicted.
A new AI model has been developed to help doctors determine the extent of cancer within the prostate gland, improving the effectiveness of focal therapy. The model was found to be more accurate than magnetic resonance imaging (MRI) in predicting tumor margins, reducing the chance of cancer recurrence.
A new global study published in the leading cancer journal finds that funding for cancer patient navigators improves medical outcomes, increases screening rates, and reduces healthcare costs. Navigators provide personalized care, support patients with diagnosis, treatment options, and relevant medical information.
A retrospective analysis of ambulatory cancer patients found that unmet supportive care needs are associated with increased risk for emergency department visits and hospitalizations. Patients with Black race, Hispanic ethnicity, or low health-related quality-of-life scores were more likely to experience these outcomes.
Scientists found that CXCL13-mediated recruitment of B cells helps predict response to immunotherapy treatment. This cooperation between T cells and B cells is associated with improved survival in patients treated with immunotherapy.
A study published in the Journal of the American Academy of Dermatology found that curettage and cryosurgery is an effective and safe treatment method for basal cell carcinoma. The procedure involves scraping the lesion with a curette followed by freezing, resulting in good outcomes with minimal side effects.
The FRESCO-2 phase III study demonstrated statistically significant improvements in overall survival and progression-free survival in patients with refractory metastatic colorectal cancer treated with fruquintinib. Fruquintinib showed a favorable safety profile, with patients staying on treatment almost twice as long as those on placebo.
Researchers found that patients producing high levels of Cystatin C, a protein linked to immune system suppression, had worse survival rates and were less likely to benefit from immunotherapy. This suggests that Cystatin C may play a role in the failure of cancer immunotherapy.
Researchers at the University of Malaga develop a new therapy using manual techniques and stretching to reduce pain and improve mobility in women with axillary web syndrome after breast cancer. The therapy, consisting of 15 sessions, has shown significant results in reducing evolution time of lymphatic thrombi.
Cancer cells can hide and escape therapies leading to recurrence. Researchers identify three possible mechanisms: cancer stem cells, polyploidy, and senescence. Combination treatments involving chemoradiation-induced transitory senescence and senolytic therapies may be effective in preventing repopulation.
Researchers at University Hospital Bonn have developed a new approach to predict therapy response in patients with metastatic renal cell carcinoma by incorporating two simple blood parameters, CRP and albumin. This method improves the prediction of treatment response, especially in patients with disease control in the first follow-up.
Researchers discuss the potential of glucocorticoid-induced TNFR-related protein (GITR) as a target for cancer immunotherapy. Preclinical studies have shown potent anti-tumor efficacy, but clinical trials have yielded inconsistent results due to complexities in immune responses and antibody structure.
Researchers have found a hidden mechanism connecting cancer and diabetes, where cancer cells don't respond well to insulin, leading to faster cancer growth. Insulin resistance can also cause muscle loss and strength decline in cancer patients.
A randomized phase II study found that adding metformin to androgen deprivation therapy did not reduce the risk of metabolic syndrome or improve PSA response in patients with advanced prostate cancer. Metformin showed some antitumor effects through mTOR inhibition, but these were not significant.
Researchers have created a new prediction tool to evaluate the benefits of blood cancer treatments, filling a gap in previous versions. The ESMO-MCBS:H v1.0 tool uses a validated algorithm to assess clinical benefits, survival data, and quality of life, providing a transparent assessment for clinicians.
Researchers developed outcome indicators to measure health issues in children with cancer, allowing for improvement in care and treatment. The indicators consider physical, psychosocial, and neurocognitive outcomes, providing a clear and comparable measurement of quality of survival.
Fruquintinib has shown statistically significant improvement in overall survival and progression-free survival rates for patients with metastatic colorectal cancer. The median survival rate was 7.4 months, with a 34% reduction in death compared to the placebo group.
A study by Martin-Luther-University Halle-Wittenberg found a link between high levels of IGF2BP2 and faster-growing bowel cancer tumours with chemotherapy resistance. The protein's role in cell growth and metabolism may lead to the development of new diagnostic procedures and therapeutic strategies.
A patient with kidney cancer overcame several metastases with temsirolimus, leading researchers to identify key mutations that make this treatment effective. The study found that patients with USP9X mutations have altered autophagy and respond better to temsirolimus.
The Ontario Institute for Cancer Research (OICR) has awarded six research teams with two-year funding to pursue innovative cancer treatments and technologies. The projects focus on personalized medicine, accessible genetic testing, and improving patient engagement.
A new study published in JNCCN found that taking alectinib, a medication for advanced lung cancer, with a full breakfast or lunch resulted in higher drug concentrations than with a low-fat breakfast. This could impact treatment efficacy and survival rates for patients.
A study found that even insured patients with diabetes use crowdfunding platforms like GoFundMe to cover excess medical expenses, including uncovered co-pays and life-saving care. Researchers urge policymakers to consider these needs when developing affordable diabetes care policies.
A study has identified a potential treatment target for prostate cancer that is resistant to hormone therapy, a protein modification involving TRAF4. The researchers found that TRAF4 promotes the spread of cancer and may be associated with a new treatment option for patients.
Researchers have identified LP-284 as a novel acylfulvene compound with anti-tumor activity against non-Hodgkin's lymphoma. The compound exerts nanomolar potency in 15 NHL cell lines and prolongs survival of mantle cell lymphoma xenograft mice, making it a potential therapeutic option for patients with HR or TC-NER deficiency.
Researchers at Mass General Cancer Center describe the evolution of proton therapy, its benefits to patients, and efforts to increase access worldwide. They highlight advancements in machine size reduction and treatment efficiency, paving the way for global democratisation.
Researchers found that rare brain tumor patients struggle to access therapy and experience devastating psychological impact after diagnosis. The study calls for improved mental health services and specialized support for these patients.
Researchers have made a breakthrough in treating melanoma by adding an mRNA vaccine tailored to individual tumour genetics to common immunotherapy, significantly improving survival and disease recurrence rates. After two years, cancer-free survival increased to 78.6%, and the risk of death or cancer returning was reduced by 44%.
State palliative care laws are associated with an increased likelihood of dying at home or in hospice among decedents from cancer. Passage of these laws may be an effective policy intervention to increase the number of seriously ill patients who experience their death in such locations.
A retrospective study found a 24% response rate to Docetaxel among patients with stage IV non-small cell lung cancer who experienced progression on immunotherapy. The median progression-free survival was 3 months, suggesting chemotherapy may still play an important role in treatment after immunotherapy failure.
A new observational study published in BMJ Open found that long Covid can have a devastating effect on daily lives, with fatigue impacting social activities, work, and relationships. The study's findings suggest that long Covid can leave people with worse fatigue and quality of life than some cancers.
Researchers discovered that tumor mutation burden is a fundamental predictor of survival, independent of clinical presentation metrics. Survival was better at both low and high extremes of mutation burden, contradicting previous assumptions about the relationship between mutation burden and survivability.
Researchers created a new type of wound dressing material using advanced polymers, enabling customized dressings with fine-tuned surface adhesion. The material has potential applications in burn treatment and drug delivery for cancer patients, providing constant medication release outside the clinic setting.
A network meta-analysis of 10 studies found expert panel-based and computer-based aesthetic outcome evaluation scored lower than patient-perceived outcomes. Standardization of tools with racially and culturally inclusive patient-reported measures is needed to improve clinical assessment of breast cancer patients.
Researchers found that only 6.8% of cancer patients underwent genetic testing within two years of diagnosis, with lower rates among Black, Hispanic, and Asian patients. The low rates are attributed to lack of integration of test results into cancer management and prevention.
Researchers analyzed BORIS mutations and protein expression in breast cancer tissue samples, finding frequent mutations associated with breast carcinoma progression. The study suggests the BORIS gene as a potential biomarker for breast cancer.
Erdafitinib achieves tumor-agnostic benefits across 16 cancer types, including urothelial, lung, and other cancers. The trial demonstrated a disease control rate of 73.7% and clinical benefit rate of 45.6%, with notable improvements in pancreatic and cholangiocarcinoma patients.
A recent study found that germline genetic testing after cancer diagnosis is underutilized, with rates significantly lower among Asian, Black, and Hispanic patients compared to non-Hispanic whites. The study, published in JAMA, suggests disparities in access to genetic testing by race.
Patients with advanced kidney cancer who receive second-line treatment with a combination of atezolizumab and cabozantinib do not experience improved progression-free survival or overall survival compared to those treated with cabozantinib alone. The study also finds higher toxicity levels in patients receiving the combination therapy.
The Phase 3 S1826 trial demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma treated with nivolumab and chemotherapy. The therapy was well-tolerated, with few serious immune-related side effects.
A phase 3 clinical trial by Dana-Farber Cancer Institute has shown vorasidenib significantly prolongs progression-free survival and delays radiation and chemotherapy for patients with Grade 2 IDH-mutant glioma. Treatment with vorasidenib can delay cognitive dysfunction in patients and preserve their quality of life.
A new targeted therapy drug vorasidenib has been shown to extend treatment time without worsening glioma in people with IDH1 and IDH2 mutations. The study suggests a possible new treatment option for slow-growing but deadly brain tumors, delaying chemotherapy and radiation.
A study published in JAMA Oncology suggests that stopping immunotherapy after two years for patients with advanced non–small cell lung cancer who remain responsive may be a reasonable strategy, providing sustained clinical benefit. The findings provide reassurance for patients and their healthcare providers.
A study found that adding ribociclib to hormone therapy significantly improves invasive disease-free survival rates in patients with stage 2 or 3 HR positive/HER2 negative breast cancer. The combination therapy reduced the risk of cancer recurrence by 25%, with a three-year invasive disease-free survival rate of 90.4%.
A Phase II trial led by MD Anderson Cancer Center showed that zanidatamab achieved a 41% confirmed objective response rate and durable responses in HER2-positive biliary tract cancer. This represents the largest study of a HER2-targeted drug in BTC, providing evidence for its potential as a new treatment option.
A phase II trial showed that patients with extensive stage SCLC expressing the Schlafen-11 gene had significantly longer progression-free survival when treated with atezolizumab and talazoparib. The study demonstrates improved outcomes for patients with SLFN11-positive SCLC, paving the way for personalized therapy approaches.
A phase 2 trial found that immune checkpoint inhibitor pembrolizumab had a durable antitumor effect in 24 of 57 patients with metastatic brain cancer. The study achieved its primary endpoint, with median overall survival of 8 months and seven patients surviving longer than two years.
ComboMATCH initiates patient enrollment to test new cancer drug combinations guided by tumor biology, exploring precision medicine and targeting proteins that control cancer growth. The project aims to identify beneficial therapies for patients with rare malignancies and/or rare molecular abnormalities.
Researchers at UCLA Health highlight the impact of test results on lung cancer screening adherence and the potential unnecessary use of axillary ultrasound in breast cancer diagnostics. Meanwhile, a new AI system helps check endotracheal tube placement with high accuracy and user satisfaction.
The SISAQOL-IMI Consortium establishes an international consensus on patient-reported outcomes in cancer trials, aiming to improve the use of PROs. The new standards will enhance patient involvement and ensure the relevance of recommendations to the patient community.
Researchers developed a bio-sensing technology that measures PD1 ligand functionality to predict patient response to anti-PD1 therapy. This technology enables accurate prediction of patient response and tailoring treatments accordingly, improving cancer patients' lives.
A large study tracked CIPN in over 1,100 breast cancer patients treated with taxanes, showing persistent sensory and motor symptoms with more severe symptoms with paclitaxel than docetaxel. The study defines a risk prediction model to help doctors individualize patient care.
The SWOG Cancer Research Network will present 30 abstracts at the ASCO 2023 annual meeting, highlighting primary results from trials S1011, S1826, S1714, and S1929. Additionally, analysis from the S1609 DART trial will be shared publicly during the meeting.
CNIO researchers review the anticancer effects of various diets, including caloric restriction, ketogenic diet, and intermittent fasting. They argue that precision nutrition can be used to treat specific cancers based on tumor metabolism and patient characteristics.
A phase 3 trial found that extending lymphadenectomy beyond the standard procedure does not reduce disease recurrence or improve survival in patients with locally advanced bladder cancer. Instead, it increases the risk of adverse events and post-surgical death.
Researchers discuss chemotherapeutic resistance in recurring ovarian cancer, focusing on the unfolded protein response and its effect on polyploid giant cancer cells. Understanding this mechanism could lead to investigating cancer cell molecular mechanisms and potential therapeutic strategies.
UMC Utrecht researchers are conducting two new projects to treat cancer using image-guided interventions. One project uses MRI-guided radiotherapy for locally advanced pancreatic cancer, while the other employs ultrasound techniques for head and neck cancers.
Researchers have discovered that HER3 plays a crucial role in promoting cell survival in metastatic colorectal and pancreatic cancer. The surrounding liver microenvironment activates HER3, making it an emerging therapeutic target for these types of cancer.
A new study highlights the need for standardized terminology, educational materials, and validated taste assessment methods to support cancer patients with taste loss. Clinicians' lack of knowledge about this issue can lead to poor patient care and outcomes.
Researchers have found a compound that can prevent cisplatin-induced renal toxicity and improve the outcomes of cancer treatment. The aromatic ketone 2',4',6'-trihydroxyacetophenone (THA) inhibits the CCBL1-mediated metabolism of cisplatin, reducing its toxic effects without affecting its potency.
A clinical trial combining TVB-2640 and bevacizumab showed a six-month progression-free survival improvement in patients with recurrent high-grade glioblastoma, warranting further study. The treatment's side effects were mild, but the overall survival of participants was not statistically significant compared to historic controls.